Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (2797)	6/21/2011 6:23:24 AM
From: Jeffry K. Smith	Respond to of 3027

Do you feel that the discolsure of this paper is a "possibly bearish" event (because of a presumed delay in moving forward) I've read about elsewhere?

To: Ian@SI who wrote (2797)	1/26/2012 7:53:08 PM
From: tuck	Respond to of 3027

"Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure/activity relationship study." >>Glycobiology. 2011 Sep;21(9):1194-205. Epub 2011 Apr 22. Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure/activity relationship study. Roy S, Lai H, Zouaoui R, Duffner J, Zhou H, P Jayaraman L, Zhao G, Ganguly T, Kishimoto TK, Venkataraman G. SourceMomenta Pharmaceuticals, Cambridge, MA 02142, USA. AbstractA series of size-defined low-molecular-weight heparins were generated by regioselective chemical modifications and profiled for their in vitro and in vivo activities. The compounds displayed reduced anti-coagulant activity, demonstrated varying affinities toward angiogenic growth factors (fibroblast growth factor-2, vascular endothelial growth factor and stromal cell-derived factor-1a), inhibited the P-selectin/P-selectin glycoprotein ligand-1 interaction and, notably, exhibited anti-tumor efficacy in a murine melanoma experimental metastasis model. Our results demonstrate that modulating specific sequences, especially the N-domains (-NS or -NH(2) or -NHCOCH(3)) in these polysaccharide sequences, has a major impact on the participation in a diverse range of biological activities. These results also suggest that the 6-O-sulfates, but not the 2-O-sulfates, critically affect the binding of a desulfated derivative to certain angiogenic proteins as well as its ability to inhibit P-selectin-mediated B16F10 melanoma metastases. Furthermore, N-desulfation followed by N-acetylation regenerates the affinity/inhibition properties to different extents in all the compounds tested in the in vitro assays. This systematic study lays a conceptual foundation for detailed structure function elucidation and will facilitate the rational design of targeted heparan sulfate proteoglycan-based anti-metastatic therapeutic candidates.<< If this resulted in anything beyond M402, it's not listed in the pipeline chart.Cheers, Tuck